Abstract library

329 results for "size".
#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: MD, MSc Dirk-Jan van Beek
#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K, ...
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#2762 Finding the Risk Factors Associated with Neuroendocrine Tumors of Rectum
Introduction: Neuroendocrine tumors usually exhibits aggressive clinical behaviour and exclusive histopathological features. 60 to 70% of rectal NETs are asymptomatic.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zai S S A, ...
#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Alberto Carmona-Bayonas
#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab
Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Elspeth Saunders
Authors: Saunders E, Demirel S, Kim S, Skelly R, ...
#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia
#2844 Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis
Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D. Jisup Kim
Authors: Kim J, Kim J Y, Oh E H, Yang D H, ...
#2925 A Single Centre Experience of Open Surgery for Pancreatic Insulinomas on 88 Patients
Introduction: Insulinomas are functioning pancreatic neuroendocrine neoplasms (NENs), typically small and with a benign clinical course in more than 90% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto